Keytruda keeps fueling Merck’s run, but CEO Frazier not ‘comfortable’ with future growth prospects

25th October 2018 Uncategorised 0

Merck & Co. has a jet engine for growth in its oncology star Keytruda, but long-term it needs more than cancer to keep growth coming. How, then, to diversify? Dealmaking, for one thing, CEO Ken Frazier said Thursday, but he didn’t offer many details on its shopping plans.

More: Keytruda keeps fueling Merck’s run, but CEO Frazier not ‘comfortable’ with future growth prospects
Source: fierce